Pamiparib + Temozolomide
PNOC017
University of California, San Francisco · Phase 1 · Active, not recruiting · Enrollment 78
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
Pamiparib + Temozolomide
University of California, San Francisco · Phase 1 · Active, not recruiting · Enrollment 78
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.